Transaction DateRecipientSharesTypePriceValue
20th October 2020Peter W. Sonsini1,426,354Conversion of derivative$0.00
20th October 2020Peter W. Sonsini1,858,716Conversion of derivative$0.00
20th October 2020Scott D Sandell1,426,354Conversion of derivative$0.00
20th October 2020Peter W. Sonsini311,111Open or private purchase$18.00$5,599,998.00
20th October 2020Peter W. Sonsini699,163Conversion of derivative$0.00
20th October 2020Scott D Sandell1,858,716Conversion of derivative$0.00
20th October 2020Scott D Sandell699,163Conversion of derivative$0.00
20th October 2020Scott D Sandell791,214Conversion of derivative$0.00
20th October 2020Peter W. Sonsini1,433,459Conversion of derivative$0.00
20th October 2020Peter W. Sonsini791,214Conversion of derivative$0.00
Regulus Therapeutics
Regulus Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Regulus Therapeutics, Inc. is a biopharmaceutical company. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases.


Ticker: RGLS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1505512
Employees: 21
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $23 M (0%)
Other Assets, Current: $573 Th (-53%)
Assets, Current: $29 M (-29%)
Property, Plant and Equipment, Net: $684 Th (-25%)
Other Assets, Noncurrent: $387 Th (-20%)
Assets: $30 M (-29%)
Accounts Payable, Current: $1 M (-22%)
Accrued Liabilities, Current: $1 M (17%)
Liabilities, Current: $21 M (-2%)
Other Liabilities, Noncurrent: $217 Th (-53%)
Liabilities: $21 M (-3%)
Common Stock, Value, Issued: $36 Th (71%)
Common Stock, Shares, Issued: $36 M (70%)
Additional Paid in Capital, Common Stock: $433 M (0%)
Retained Earnings (Accumulated Deficit): $424 M (3%)
Stockholders' Equity (Parent): $9 M (0%)
Liabilities and Equity: $30 M (-29%)
Research and Development: $4 M (-42%)
General and Administrative Expenses: $2 M (-51%)
Operating Income/Loss: $6 M (-46%)
Provision for income taxes: $0 (-100%)